The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Oxytocin

Oxytocin · OXT · Pitocin · Syntocinon

C
Animal replicated
RouteInjectableFDA-approved
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ / OXT / Pitocin / Syntocinon — Peptide Hormone, Oxytocin Receptor Agonist, Nonapeptide.
Why people use it
Used primarily for cognitive support and sexual health.
What the evidence supports
Before engaging with the contested behavioral pharmacology, it's worth grounding the chapter in what oxytocin does reliably and well — its FDA-approved obstetric applications represent among the most evidence-backed pharmaceutical uses in medicine.
If you only read one thing

Oxytocin's endogenous biology is real and extraordinary — it regulates parturition, lactation, pair bonding, maternal behavior, social recognition, trust, and fear processing through a well-characterized receptor system. Its clinical use for obstetric indications is among the most established in medicine. The crisis is in the exogenous behavioral pharmacology: intranasal bioavailability is approximately 2%; whether nose-to-brain transport delivers functionally relevant CNS concentrations is disputed; the trust enhancement result that launched the field has failed large-scale pre-registered replication; meta-analyses of intranasal oxytocin for autism, schizophrenia, and social anxiety consistently find null or inconsistent effects; and the behavioral effects that do appear are strongly context-dependent and can point in antisocial as well as prosocial directions depending on context, baseline traits, and the specific social configuration. The molecule that launched a thousand 'love hormone' headlines and an OTC nasal spray market may not reliably do what either has claimed.

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
10human RCTs4human studies5animal3in vitro

Oxytocin has extensive controlled evidence and FDA-approved IV/IM obstetric use; intranasal behavioral/social findings are mixed and should not be treated as reliable enhancement evidence.

Evidence reality check
Human evidence
14 human studies
10 randomized; 4 observational.
Preclinical base
8 lab signals
5 animal; 3 in-vitro/mechanistic.
Evidence snapshot
Before engaging with the contested behavioral pharmacology, it's worth grounding the chapter in what oxytocin does reliably and well — its FDA-approved obstetric applications represent among the most evidence-backed pharmaceutical uses in medicine.
From the chapter quick-reference block.

Oxytocin is simultaneously one of the most important hormones in the human body and one of the most overhyped molecules in popular neuroscience. These two facts are not in conflict — they are both true, and both need to be held simultaneously.

The central tension resolved: the endogenous oxytocin system genuinely regulates some of the most profoundly important aspects of human life — childbirth, infant feeding, pair bonding, social trust, maternal love. The FDA-approved obstetric applications (Pitocin for labor induction and PPH prevention) represent pharmacology that is unambiguously among the most well-established in medicine. The behavioral applications of exogenous oxytocin are where the science has not kept pace with the excitement. The trust enhancement finding did not replicate at scale. The autism trials are consistently null at primary endpoints. The intranasal route's ability to deliver pharmacologically meaningful concentrations to the human brain is assumed, not proven. The effects that do appear are context-dependent in ways that include antisocial as well as prosocial directions.

What this means for different audiences: for physicians considering prescribing compounded intranasal oxytocin for psychiatric or behavioral indications — the current evidence does not support routine clinical use, and informed consent requires honest communication about the limited and inconsistent evidence base. For researchers — the field needs larger pre-registered trials at higher doses with confirmed brain delivery measurement. For community users — OTC oxytocin nasal sprays are not supported by the evidence and their content is unverified; compounded intranasal oxytocin with a prescription is a legitimate product from a quality standpoint, but its behavioral benefits are not established in healthy adults. For partners considering administering oxytocin to each other to 'enhance bonding' — this is pharmacological manipulation of your own and another person's social neurobiology on the basis of a story that science has substantially complicated; proceed with appropriate reflection.

Properties
✓ FDA-approved✓ Human RCT
Half-life
plasma half-life approximately 1-6 minutes (rapidly degraded by oxytocinases, primarily cystyl aminopeptidase/leucyl-cystinyl aminopeptidase)
Evidence
CAnimal replicated
FDA-Approved Uses
IV/IM oxytocin (Pitocin): FDA-approved for (1) labor induction in cases with medical indication (preeclampsia, premature rupture of membranes, maternal diabetes, post-term pregnancy); (2) stimulation or reinforcement of labor (uterine inertia); (3) control of postpartum hemorrhage and uterine bleeding. WHO Essential Medicine for postpartum hemorrhage. HISTORICAL: intranasal oxytocin (Syntocinon) was once marketed in the US for postpartum milk let-down; this formulation has been discontinued in the US. NOT FDA-APPROVED: intranasal oxytocin for behavioral/social uses, autism, social anxiety, PTSD, or any psychiatric/neurobehavioral indication.
The Central Controversy
The 'love hormone' narrative — that intranasal oxytocin reliably enhances trust, social bonding, empathy, and prosocial behavior — is not supported by the replication evidence. The Kosfeld 2005 Science paper ('Oxytocin increases trust in humans') launched the field and the brand. A large pre-registered replication study (Declerck et al., n=677) found no significant trust-enhancing effect. A meta-analysis of intranasal oxytocin and trust found no overall significant effect. A 2024 meta-analysis of 12 ASD RCTs found no significant effect on social impairments at standard doses. The behavioral effects of intranasal oxytocin are context-dependent, population-specific, dose-sensitive, and frequently fail to replicate across sites and methodologies.
Bioavailability Problem
Intranasal nasal bioavailability of oxytocin: approximately 2% (rat pharmacokinetic study; nose-to-brain transport demonstrated in animal models and rhesus macaques). BBB penetration from peripheral blood: negligible (oxytocin is a hydrophilic peptide; blood-brain barrier effectively excludes it at peripheral concentrations). The mechanism for intranasal CNS access appears to be direct transport along olfactory and trigeminal nerve fibers — a real pathway, but whether the concentrations that reach the brain via this route are functionally significant for behavioral endpoints is unresolved and actively debated.
Context Dependency — The Double Edge
Oxytocin does not uniformly promote prosocial behavior. Its effects are strongly modulated by social context: in safe, cooperative contexts it promotes trust, affiliation, and approach. In threatening or uncertain contexts, it can enhance defensive, fearful, or even aggressive behaviors. It increases in-group favoritism while potentially increasing out-group bias — the 'ethnocentrism effect' documented by De Dreu et al. It heightens sensitivity to social cues whether those cues are positive or negative. The 'love hormone' framing captures approximately half of the pharmacological story and ignores the other half.
Delivery Routes and Their Evidence Profiles
IV/IM: 100% bioavailability; obstetric standard; not used for behavioral applications. Intranasal: standard behavioral research route; ~2% nasal bioavailability; nose-to-brain transport real but contested in magnitude; all behavioral research uses this route. SubQ: peripheral delivery; minimal BBB penetration; used in some compounding contexts; little behavioral evidence. Sublingual (troches): limited data; oral/sublingual oxytocin extensively degraded by peptidases. IV (wellness): IV oxytocin for behavioral purposes (e.g., 'IV therapy' wellness clinics) produces peripheral effects but not established CNS behavioral effects; safety concerns in non-obstetric IV context.
WADA / Regulatory Status
Oxytocin is not on the 2026 WADA Prohibited List. IV/IM oxytocin (Pitocin): FDA-approved; prescription medication. Intranasal oxytocin: not FDA-approved for any behavioral/psychiatric indication; available through compounding pharmacies with prescription; over-the-counter 'oxytocin nasal sprays' exist but these are not FDA-regulated pharmaceutical products and potency/purity is unverified.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Check interactions